Zacks Investment Research upgraded shares of Scholar Rock (NASDAQ:SRRK) from a hold rating to a buy rating in a research note published on Friday, Zacks.com reports. The firm currently has $14.00 price objective on the stock.

According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “

Separately, ValuEngine upgraded Scholar Rock from a hold rating to a buy rating in a report on Thursday, August 1st.

NASDAQ SRRK opened at $11.73 on Friday. The stock has a 50-day simple moving average of $11.11 and a 200 day simple moving average of $15.98. The company has a market capitalization of $387.92 million, a PE ratio of -3.72 and a beta of 0.08. The company has a current ratio of 5.88, a quick ratio of 5.88 and a debt-to-equity ratio of 0.04. Scholar Rock has a 12 month low of $9.30 and a 12 month high of $30.00.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.07). The company had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.38 million. As a group, sell-side analysts predict that Scholar Rock will post -1.7 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of SRRK. Price T Rowe Associates Inc. MD grew its stake in Scholar Rock by 57.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,303,747 shares of the company’s stock valued at $20,677,000 after acquiring an additional 477,174 shares during the period. Jefferies Group LLC acquired a new position in Scholar Rock in the second quarter valued at about $4,603,000. Redmile Group LLC grew its stake in Scholar Rock by 16.4% in the first quarter. Redmile Group LLC now owns 2,051,089 shares of the company’s stock valued at $38,540,000 after acquiring an additional 289,682 shares during the period. Vanguard Group Inc. grew its stake in Scholar Rock by 48.5% in the second quarter. Vanguard Group Inc. now owns 868,824 shares of the company’s stock valued at $13,780,000 after acquiring an additional 283,880 shares during the period. Finally, CVI Holdings LLC acquired a new position in Scholar Rock in the second quarter valued at about $2,655,000. 58.52% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.

Read More: How to trade the most active stocks

Get a free copy of the Zacks research report on Scholar Rock (SRRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.